阿加曲班与低相对分子质量肝素联合银杏达莫治疗进展性脑栓塞患者的临床研究

目的探讨阿加曲班与低相对分子质量肝素(LMWH)联合银杏达莫治疗进展性脑栓塞患者的临床应用价值。方法将我院2013年6月~2016年6月收治的进展性脑栓塞患者78例随机分为2组各39例,对照组给予阿加曲班联合银杏达莫治疗,观察组给予阿加曲班、LMWH联合银杏达莫治疗,2组治疗时间均为患者入院至出院始末,出院后均随访观察1个月。观察比较2组治疗前后生存质量评分、住院时间和住院期间不良反应发生率。结果 (1)治疗前2组生存质量评分比较,差异均无统计学意义(P0.05);治疗后2组生存质量评分均明显高于治疗前,且观察组生存质量评分明显高于对照组,差异均有统计学意义(P0.05)。观察组住院时间为(3.8±1.5)d,明显短于对照组的(5.7±3.1)d,差异有统计学意义(P0.05)。(2)2组住院期间发生的不良反应主要为恶心、呕吐、头晕、皮肤过敏、出血、过敏性休克和一过性转氢酶升高,在及时停药并经积极对症处理后均明显缓解。观察组在住院期间的不良反应发生率为7.69%,明显低于对照组的25.64%,差异有统计学意义(P0.05)。结论阿加曲班、LMWH联合银杏达莫在进展性脑栓塞患者的治疗中具有较高的临床效果,能显著提高患者生活质量,缩短住院时间,同时能有效降低住院期间不良反应发生率,安全性高。

Study of Argatroban with low Molecular Weight Heparin Combined with Ginkgo Dipyridamole in the Treatment of Patients with Progressive Cerebral Embolism

Objective To compare argatroban and low molecular weight heparin (LMWH)combined with ginkgo leaf extract and dipyridamole in the treatment of progressive cerebral embolism in patients with clinical application value.Methods In our hospital from June 2013 to June 2016 the development of cerebral embolism patients treated 78 cases were randomly divided into 2 groups with 39 cases in each group,the control group was given argatroban combined with ginkgo leaf extract and dipyridamole treatment,the observation group was given argatroban,LMWH combined with ginkgo leaf extract and dipyridamole treatment,treatment time of 2 groups of patients were admitted to hospital discharge through observation,1 months were followed up after discharge.The survival quality score,length of stay and incidence of adverse reaction were observed and compared between the 2 groups before and after treatment.Results 2 groups of quality of life score comparison before treatment,there were no significant differences (P ＞ 0.05);quality of life scores of the 2 groups after treatment were significantly higher than those before treatment,and the quality of life in the observation group was significantly higher than that in control group,the differences were statistically significant (P ＜ 0.05).The hospitalization time of observation group was (3.8 ± 1.5) d,significantly shorter than that of control group (5.7 ± 3.1) d,the difference was statistically significant (P ＜ 0.05).The adverse reaction in the 2 groups during hospitalization were mainly nausea and vomiting,dizziness,skin allergies,bleeding,anaphylactic shock and a transhydrogenase increased in time after positive symptomatic treatment were significantly alleviated.The incidence rate of adverse reactions in the observation group during hospitalization was 7.69％,significantly lower than that of the control group (25.64％),the difference was statistically significant (P ＜ 0.05).Conclusion The clinical effect of argatroban,LMWH combined with ginkgo leaf is higher in the treatment of patients with progressive cerebral embolism in,can significantly improve the quality of life of patients,shorten the hospitalization time,at the same time can effectively reduce the incidence of adverse reactions during hospitalization,high safety.